Trial Profile
A Phase III, Open Label, Randomized, Controlled, Multicenter Study, comparing Eribulin with S1, to assess Health-related Quality of Life (HRQoL) in the Treatment of Her2 negative Metastatic Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Gimeracil/oteracil/tegafur
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESQ
- 11 May 2020 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2016 Status changed from not yet recruiting to recruiting.
- 25 May 2016 New trial record